Blauvelt, A. ., Rich, P., Sofen, H., Lambert, J., Merola, J., Lebwohl, M., Hippeli, L., Kisa, R., Banerjee, S., & Kimball, A. (2022). Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine, 6(4), s41.